Herantis Pharma has carried out an offering of new shares in a directed share issue to institutional and other qualified investors.
“We thank our existing shareholders, many of whom participated in this directed issue, for their continued support in developing HER-096 as a promising disease-modifying drug candidate for Parkinson’s disease. We are delighted to welcome the new investors and especially EIC Fund (European Innovation Council Fund) as new shareholders of the company,” says the CEO of Herantis, Antti Vuolanto.
Photo: iStock
Advertisement
